1-((4R,5R,7R,8R)-8-hydroxy-7-(hydroxymethyl)-1,6-dioxaspiro[3.4]octan-5-yl)pyrimidine-2,4(1H,3H)-dione | 1255860-33-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-((4R,5R,7R,8R)-8-hydroxy-7-(hydroxymethyl)-1,6-dioxaspiro[3.4]octan-5-yl)pyrimidine-2,4(1H,3H)-dione
• 英文别名: 1-[(4R,5R,7R,8R)-8-hydroxy-7-(hydroxyl-methyl)-1,6-dioxaspiro[3.4]octan-5-yl]pyrimidine-2,4(1H,3H)-dione；1-(2-O,2-C-ethano-β-D-ribofuranosyl)uracil；1-[(4R,5R,6R,8R)-5-hydroxy-6-(hydroxymethyl)-3,7-dioxaspiro[3.4]octan-8-yl]pyrimidine-2,4-dione；1-[(4R,5R,6R,8R)-5-hydroxy-6-(hydroxymethyl)-1,7-dioxaspiro[3.4]octan-8-yl]pyrimidine-2,4-dione
• CAS: 1255860-33-3
• 化学式: C₁₁H₁₄N₂O₆
• 分子量: 270.242
• InChiKey: UTAJPKQGORLGGP-PNHWDRBUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  108
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-((4R,5R,7R,8R)-8-hydroxy-7-(hydroxymethyl)-1,6-dioxaspiro[3.4]octan-5-yl)pyrimidine-2,4(1H,3H)-dione 在 N,N-二甲基丙烯基脲 、 三正丁胺 、 三丁基焦磷酸铵 、 三氯氧磷 作用下， 生成 2′-deoxy-2′-spirooxetane uridine triphosphate
  参考文献：
  名称：

  Use of 2′-Spirocyclic Ethers in HCV Nucleoside Design

  摘要：

  Conformationally restricted 2'-spironucleosides and their prodrugs were synthesized as potential anti-HCV agents. Although the replicon activity of the new agents containing pyrimidine bases was modest, the triphosphate of a 2'-oxetane cytidine analogue demonstrated potent intrinsic biochemical activity against the NS5B polymerase, with IC50 = 8.48 mu M. Activity against NS5B bearing the S282T mutation was reduced. Phosphoramidate prodrugs of a 2'-oxetane 2-amino-6-O-methylpurine nucleoside demonstrated potent anti-HCV activity in vitro, and the corresponding triphosphate retained similar potent activity against both wild-type and S282T HCV NS5B polymerase.

  DOI：

  10.1021/jm401224y
• 作为产物：
  描述：

  甲基 2,3,5-三-O-苄基-D-呋喃核糖苷 在 吡啶 、 4-二甲氨基吡啶 、 sodium periodate 、 四氧化锇 、 N,O-双三甲硅基乙酰胺 、 氢气 、 palladium(II) hydroxide 、 四氯化锡 、 戴斯-马丁氧化剂 、 甲基磺酰氯 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 二氯甲烷 、 水 、 乙腈 、 叔丁醇 为溶剂， 反应 136.5h， 生成 1-((4R,5R,7R,8R)-8-hydroxy-7-(hydroxymethyl)-1,6-dioxaspiro[3.4]octan-5-yl)pyrimidine-2,4(1H,3H)-dione
  参考文献：
  名称：

  Uracyl Spirooxetane Nucleoside Phosphoramidates

  摘要：

  这项发明涉及一种在治疗感染丙型肝炎病毒（HCV）的患者中有用的立体化学纯尿嘧啶螺环氧烷核苷磷酸酰胺。

  公开号：

  US20130244968A1

文献信息

• SUBSTITUTED NUCLEOTIDE ANALOGS
  申请人：ALIOS BIOPHARMA, INC.

  公开号：US20130164261A1

  公开（公告）日：2013-06-27

  Disclosed herein are phosphorothioate nucleotide analogs, methods of synthesizing phosphorothioate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphorothioate nucleotide analogs.

  本文披露了磷硫酸酯核苷类似物，合成磷硫酸酯核苷类似物的方法，以及利用磷硫酸酯核苷类似物治疗病毒感染、癌症和/或寄生虫病等疾病和/或症状的方法。
• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：PHARMASSET INC

  公开号：WO2012075140A1

  公开（公告）日：2012-06-07

  Disclosed herein are 2'-spiro-nucleosides of formula I and derivatives thereof useful for treating a subject infected by hepatitis C virus or dengue virus. Formula (I), where z is a four-or five-membered ring selected from among radicals a-o represented by de following structures (II) where * represents the point of attachment to the 2'-carbon.

  本文披露了公式I的2'-螺环核苷及其衍生物，用于治疗感染丙型肝炎病毒或登革病毒的受试者。公式(I)中，z是从以下结构(II)所代表的基团a-o中选择的四元或五元环。其中*表示连接到2'-碳的位置。
• [EN] URACYL SPIROOXETANE NUCLEOSIDES<br/>[FR] NUCLÉOSIDES DE SPIROOXÉTANE D'URACILE
  申请人：CENTOCOR ORTHO BIOTECH PRODUCT

  公开号：WO2010130726A1

  公开（公告）日：2010-11-18

  Compounds of the formula (I) including any possible stereoisomers thereof, wherein: R4 is a monophosphate, diphosphate or triphosphate ester; or R4 is formula (II) or formula (III), R7 is optionally substituted phenyl, optionally substituted naphthyl, or optionally substituted indolyl; R8 and R8 are hydrogen, C1-C6alkyl, benzyl, or phenyl; or R8 and R8 form C3-C7cycloalkyl; R9 is C1-C10alkyl, C3-C7cycloalkyl, phenyl or phenyl-C1-C6alkyl, wherein the phenyl moiety in phenyl or phenyl-C1-C6alkyl is optionally substituted; or a pharmaceutically acceptable salt or solvate thereof; pharmaceutical formulations and the use of compounds I as HCV inhibitors.

  化合物的公式（I）及其可能的立体异构体，其中：R4是单磷酸酯、二磷酸酯或三磷酸酯；或R4是公式（II）或公式（III），R7是可选择取代的苯基、可选择取代的萘基或可选择取代的吲哚基；R8和R8是氢、C1-C6烷基、苄基或苯基；或R8和R8形成C3-C7环烷基；R9是C1-C10烷基、C3-C7环烷基、苯基或苯基-C1-C6烷基，其中苯基或苯基-C1-C6烷基中的苯基部分可选择取代；或其药学上可接受的盐或溶剂；药物配方和将化合物I用作HCV抑制剂。
• [EN] SPIROCYCLIC NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF HEPATITIS E<br/>[FR] ANALOGUES NUCLÉOSIDIQUES SPIROCYCLIQUES POUR LE TRAITEMENT DE L'HÉPATITE E
  申请人：JANSSEN SCIENCES IRELAND UNLIMITED CO

  公开号：WO2021209427A1

  公开（公告）日：2021-10-21

  The present disclosure is directed toward spirocyclic nucleoside analogs, compositions comprising these compounds, and their use for treating hepatitis E infections.

  本公开涉及螺环核苷类似物、包含这些化合物的组合物，以及它们用于治疗甲型肝炎感染的用途。
• [EN] URACYL SPIROOXETANE NUCLEOSIDES<br/>[FR] NUCLÉOSIDES D'URACYL SPIROOXÉTANE
  申请人：JANSSEN R & D IRELAND

  公开号：WO2013174962A1

  公开（公告）日：2013-11-28

  The present invention relates to compounds of the formula I: including any possible stereoisomers thereof, wherein R9 has the meaning as defined herein,or a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HCV inhibitors, in HCV therapy.

  本发明涉及公式I的化合物，包括任何可能的立体异构体，其中R9的含义如本文所定义，或其药学上可接受的盐或溶剂。本发明还涉及制备该化合物的过程，含有它们的制药组合物以及它们在HCV治疗中单独或与其他HCV抑制剂联合使用的用途。